about
Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosisIntegration of interventional bronchoscopy in the management of lung cancerErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives[Molecular epidemiology of the lung cancer].Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).Diagnostic value of bronchoscopy, CT and transbronchial biopsies in diffuse pulmonary lymphangiomatosis: case report and review of the literature.DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients.A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.Radiofrequency ablation for non-small-cell lung cancer in a single-lung patient: case report and review of the literature.Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls.Targeting the immune system to treat lung cancer: rationale and clinical experience.A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.Nivolumab for treating non-small cell lung cancer.Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.[Stenting for superior vena cava obstruction associated with lung cancer: monocentric study]Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer.Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.Loss of RhoB expression in human lung cancer progression.Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.[KRAS and bronchial adenocarcinoma. Between disappointments and hopes].Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).[Incidence and characteristics of bronchial colonisation in patient with lung cancer: a retrospective study of 388 cases].Specificities of lung adenocarcinoma in women who have never smoked.[Lung cancer in women and pregnancy: towards a hormonal origin?][Hospital undertaking of patients with a resection of lung cancer].Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.Characteristics of lung cancer in women: importance of hormonal and growth factors.
P50
Q24307566-3CED0B5A-CBA8-48B5-BFF6-BAAC6A203EA3Q26795661-2B069C4C-2203-4090-BF5F-5E215D561D03Q27851712-F036D01E-04AF-460C-A255-A2D8E95BBBBEQ27853124-F514A823-FC68-4661-ADD8-F2709FBD8B76Q28289431-19037527-B192-4A59-BB81-468BA856064FQ30249798-9471D6F6-B4EB-4758-899B-DD845FE5B767Q35834928-289085AF-CD72-412A-B576-D10B3356E3D9Q36205317-01CA2D06-8200-4647-830E-CEA0B33474FEQ36415115-3CEFE0C2-013F-4F11-9991-22A4AAF9CC72Q36865033-512F3222-C00F-4F42-8C55-A5FECF239ADEQ37193792-FE909FEB-CEA0-40AE-9B12-1F371C50C85AQ37220424-D9306C55-A7AD-42DE-B323-1F8AED937B3AQ37618018-8948056B-7371-4B7A-B214-ADD5A258108EQ38087772-0B5021BA-40D1-470A-93AA-F26FAF1C0134Q38204478-8CCA9CFB-00DC-4F2F-B3C7-D96A77E98CEBQ38397629-4CD2FE19-CC52-419A-B292-44D6F69FDD41Q38425167-57E81409-0B90-41E2-A8CE-A19CD1019E2CQ38634988-08C278F8-7A4D-4421-AB9A-83AF2F5386A8Q38815101-F02DD18C-B4A9-4341-AB2A-9AFF9FEBBF82Q38823100-9BAF28A5-5BC6-4F5B-AAB2-EC906C821A3FQ38856262-21CBD6D2-6EC6-4AD1-9A67-CD1E5D8409D4Q39294858-E0687C6D-5015-432C-BA6E-ADD3C1353727Q39727926-F77D9CAB-9E16-4897-9E55-649A1DB0375CQ40198170-06F51FD7-9633-4027-A192-D350BEC2AD92Q40402748-E67B28F7-3F63-4443-8FA6-CFAA343A733DQ40543122-B732EF14-F2FA-410F-AB84-99D17126E31AQ40564102-630F74D0-A944-4F77-9FFF-D13A4B3E6E8CQ40709000-975FEC34-EF4F-4853-BF2B-26A4EBC8F37FQ40962196-72C6C0BF-7FAA-4682-BD46-014ED1280950Q41008161-663E2CF7-6EDF-4B69-B338-EAD77B192E49Q41162709-1B3F73A8-7E81-44BF-8419-6427304CEB65Q41538585-556AE54E-3F31-4690-B0D3-C836AF52D84CQ41683156-1B7FC33B-D357-43CA-BC7E-72806FF3CBEBQ43722122-B72EC6F8-68B4-4760-BC01-B39D566EDD7DQ43888762-BF63926F-8F84-46B9-8F95-97D5E9571DE9Q44517679-B22C659F-E2D2-490C-BDF2-9E26CCFE4C95Q44805924-555741F1-0B49-43F8-9468-64F3DF5F4342Q44846520-A7617AE7-8622-4CE3-871D-82FAA749A2E8Q45286100-F6704797-D6E3-4A89-8782-EFE0D15C608EQ45309597-F1697645-6233-40AB-9527-F46DEEA4884D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Julien Mazieres
@ast
Julien Mazieres
@en
Julien Mazieres
@es
Julien Mazieres
@nl
type
label
Julien Mazieres
@ast
Julien Mazieres
@en
Julien Mazieres
@es
Julien Mazieres
@nl
prefLabel
Julien Mazieres
@ast
Julien Mazieres
@en
Julien Mazieres
@es
Julien Mazieres
@nl
P106
P1153
6603687162
P31
P496
0000-0002-5921-7613